Subscribe: Apple Podcasts · Spotify · YouTube · Amazon Music · iHeartRadio · Pandora · RSS
Episode Summary
The wire hits. Everybody on the outside wants to buy you a drink, and you’re sitting in a hole you didn’t see coming. Cindy Eckert sold Sprout Pharmaceuticals (the company behind Addyi, what the press dubbed “female Viagra”) to Valeant for over a billion dollars in 2015. Within a year the buyer had dismantled her team, shelved the drug, and turned her vision into a line item on someone else’s balance sheet. I wanted her on the show because of what came next: she sued Valeant and got the company back, and the only reason that was possible is what her legal team wrote into the contract before the ink dried. We got into the part of the exit nobody talks about. The identity gap the day after close. The difference between a buyer who manages the spreadsheet and a buyer who believes what you believe. The specific performance obligations (marketing spend, headcount, education) that replaced “best efforts” in the deal and gave her the door back in. Real billion-dollar number, real lesson on why your legal team matters more than your banker when the Milestone 6 — Transaction Value is being papered.
Watch on YouTube
## Top 10 Takeaways- The investors who stay through the twists aren’t managing spreadsheets. They believe what you believe.
- Take a breath before you take the big check. Misaligned philosophies on day one cost a year to unwind.
- Hire owners, not employees. Skin in the game is the only thing that changes how people show up.
- “Best efforts” is the most expensive boilerplate language in your sale contract. Strike it.
- Bake specific performance obligations into the deal (marketing spend, headcount, education). That language is your door back in.
- Your investment banker matters. Your legal team matters more.
- The founder CEO loves the build. The forever CEO commands greater value because the buyer can’t buy you out of running it.
- Selling is exhilarating and excruciating. Nobody warns you about standing on the sidelines while someone else owns your baby.
- The terrifying question twelve months post-exit isn’t financial. It’s “what do you do” and “who are you now.”
- If your buyer doesn’t share your vision for the team, the team is gone within a year, and so is the mission.
Sound Bites
“It is both exhilarating and excruciating to sell your company.” (@TBD) — Cindy Eckert
“Best efforts. Well, hey, guess what? Your version of best efforts and my version of best efforts… maybe a little bit different.” (@TBD) — Cindy Eckert
“We talk a lot in entrepreneurship about who is the bank that went out and sold it with you. I got to tell you, my legal team was even more important.” (@TBD) — Cindy Eckert
“When they gave me money, I saw it as their children’s college fund. I saw it as their aging parents going into the long-term care facility. They were giving me their hard-earned money and it was my responsibility to pay it back and then some.” (@TBD) — Cindy Eckert
“What you realize is that it’s never about the money.” (@TBD) — Cindy Eckert
About This Episode
Cindy Eckert (formerly Cindy Whitehead) is the founder of Sprout Pharmaceuticals, the company that brought Addyi to market as the first FDA-approved drug for female sexual desire. She sold Sprout to Valeant for over $1 billion in 2015, then sued Valeant and got the company back when the buyer failed to meet specific performance obligations she had written into the deal. She is also the founder of The Pink Ceiling and Pinkubator, which invests in and incubates female-founded breakthrough companies. Her TEDx talk, “The DNA of a Rule Breaker,” frames her approach to disrupting industries dominated by convention.
Resources Mentioned
- Sprout Pharmaceuticals — Cindy’s pharma company, sold to Valeant for $1B+ in 2015 and later reclaimed.
- The Pink Ceiling / Pinkubator — Cindy’s investment and incubation platform for female-founded companies. — pinkceiling.com
- “The DNA of a Rule Breaker” — Cindy’s TEDx talk on female rule-breakers and leadership.
- Finish Big by Bo Burlingham — Referenced for the data point that 75% of entrepreneurs are unhappy 12 months after the sale.
- John Warrillow’s podcast — Where Ryan first heard Cindy’s story.
- EY Entrepreneurial Winning Women — Network of female entrepreneurs Ryan has interviewed.
- Leah Diagnostics (Bethany Edwards) — Pinkubator portfolio company building a flushable pregnancy test.
Connections
Phase + Module:
- Module 1 — Ownership Goals — Knowing what you want and why before the buyer shows up
- Module 9 — Operator Transition — Picking the buyer, structuring the deal, and what comes after
Milestones:
- Milestone 5 — Market Value — Why Valeant paid what they paid
- Milestone 6 — Transaction Value — Cash up front plus structured backend, and what governs the backend
- Milestone 25 — Operator Transition Plan — What happens to the team and the mission post-close
Concepts referenced:
- Three Lenses of Value — Owner’s value, market value, and transaction value as three different numbers
- Capital Allocator — What Cindy became with the Pink Ceiling after the exit
- Independence Escape Velocity — The exit hit the number; the identity didn’t follow